Therapeutic uses of allogeneic myeloid progenitor cells

Details Therapeutic uses of allogeneic myeloid progenitor cells Therapeutic uses of allogeneic myeloid progenitor cells

2005-11-08

2010-10-12

Hama, Joanne (Department: 1632)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S366000, C435S372100

Reexamination Certificate

active

07811815

ABSTRACT:
Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

REFERENCES:
patent: 6465247 (2002-10-01), Weissman et al.
patent: 6761883 (2004-07-01), Weissman et al.
patent: 7300760 (2007-11-01), Weissman et al.
patent: 2002/0086422 (2002-07-01), Weissman et al.
patent: 2003/0060425 (2003-03-01), Ahlem et al.
patent: 2005/0215473 (2005-09-01), Alvarez et al.
Cairo et al., 1992, Blood, 79: 1869-1873.
Wardley et al., 2000, British Journal of Haematology, 110: 292: 299.
Booth et al., 2001, J. Natl. Cancer Inst. Monogr., 29: 16-20.
Petersdorf et al., 2006, Center for International Blood and Marrow Transplant Research, 12: 1-12.
Sasazuki et al., 1998, The New England Journal of Medicine, 339: 1177-1185.
Rieger et al., 2009, Transplant Infectious Disease, 11: 220-226.
Oksanen et al., 1993, British Journal of Haematology, 84: 639-647.
American Red Cross. Practice Guidelines for Blood Transfusion. A Compilation from Recent Peer-Reviewed Literature, 2nd edition, 2007 [retrieved on Oct. 28, 2009]. Retrieved from the Internet:<http://www.redcross.org/www-files/Documents/WorkingWiththeRedCross/practiceguidelinesforbloodtrans.pdf> , pp. 1-64.
Theilgaard-Monch et al., 1999, Bone Marrow Transplantation, 23: 243-249.
Winthrop University Hospital, Institute for Family Care, Complete Blood Count (CBC), 2008 [retrieved on Oct. 28, 2009]. Retrieved from the Internet: <http://www.winthrop.org/CCK/Understand-Childhood-Cancers-Blood-Disorders.cfm?page=cb> pp. 1-6.
Arbor et al., Common lymphoid progenitors from MHC-mismatched donors engraft without inducing GVHD, Blood, 2003, 102: 3504.
Bitmansour et al., Myeloid progenitors protect against invasive aspergillosis andPseudomonas aeruginosainfection following hematopoietic stem cell transplantation, Blood, 2002, 100(13): 4660-7.

Affiliated with

Also associated with

Rating

Therapeutic uses of allogeneic myeloid progenitor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic uses of allogeneic myeloid progenitor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of allogeneic myeloid progenitor cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4223531